Fenofibric acid Chemical Properties

Melting point:

177-179°C

Boiling point:

486.5±35.0 °C(Predicted)

Density 

1.286±0.06 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

Chloroform (Slightly), Methanol (Slightly)

pka

3.09±0.10(Predicted)

form 

powder

color 

White to Off-White

BRN 

2058973

InChI

InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)

InChIKey

MQOBSOSZFYZQOK-UHFFFAOYSA-N

SMILES

C(O)(=O)C(OC1=CC=C(C(=O)C2=CC=C(Cl)C=C2)C=C1)(C)C

CAS DataBase Reference

42017-89-0(CAS DataBase Reference)

Safety Information

Hazard Codes 

Xn,N

Risk Statements 

36/37/38-50/53-22

Safety Statements 

26-36/37/39-61-60-24/25

RIDADR 

UN 3077 9 / PGIII

WGK Germany 

3

RTECS 

UA2453000

HazardClass 

9

PackingGroup 

III

HS Code 

29189900

Toxicity

LD50 oral in rat: 1242mg/kg

Fenofibric acid Usage And Synthesis

Chemical Properties

Fenofibric acid is a white to almost white crystalline powder that is stable under ordinary conditions and has a melting point of 179 – 183°C. Its empirical formula is C17H15ClO4 and molecular weight 318.75. Fenofibric acid is insoluble in water; its solubility increases with pH in buffered media.

Uses

Fenofibric acid, the active metabolite of fenofibrate. Increases Apolipoprotein A-Iediated High-Density Lipoprotein Biogenesis by enhancing transcription of ATP-Binding cassette transporter A1 gene in a liver X receptorependent manner

Uses

Fenofibric acid, the active metabolite of fenofibrate. Increases Apolipoprotein A-I–Mediated High-Density Lipoprotein Biogenesis by enhancing transcription of ATP-Binding cassette transporter A1 gene in a liver X receptor–dependent manner.

Uses

DPP4 inhibitor, antidiabetic

Definition

ChEBI: A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.

Metabolism

Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite, which is, in turn, conjugated with glucuronic acid and excreted in urine. In vitro and in vivo metabolism data indicate that fenofibric acid does not undergo oxidative metabolism (e.g. cytochrome P450) to a significant extent. The enzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 do not play a role in the metabolism of fenofibric acid.

Fenofibric acid(42017-89-0)Related Product Information

• (4-Chlorophenyl)[4-(1-Methylethoxy)phenyl]Methanone (Fenofibrate IMpurity)
• FENOFIBRATE RELATED COMPOUND C (25 MG) (1-METHYLETHYL 2-[[2-[4-(4-CHLOROBENZOYL)PHENOXY]-2-METHYLPROPANOYL]OXY]-2-METHYLPROPANOATE)
• Ethyl 2-(Chlorosulfonyl)acetate
• Dimethyldimethoxysilane
• Methyltriethoxysilane
• Methyltrimethoxysilane
• Stearic acid
• Folic acid
• Citric acid
• Ethoxymethylenemalononitrile
• Fenofibrate
• 2,2-Bis(hydroxymethyl)propionic acid
• 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic acid methyl ester
• Unii-4bmh7izt98
• 4-Chloro-4'-hydroxybenzophenone
• 3-[4-(4-Chlorobenzoyl)phenoxy]-2-butanone (Fenofibrate IMpurity)
• Diethyl squarate
• Squaric acid